ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2008
Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.The Yale journal of biology and medicine · 2022Pooled it
- Decoding Burkholderia Cepacia complex: recA-based species differentiation and antimicrobial susceptibility pattern.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Article
- Evaluation of antimicrobial susceptibility testing methods forJournal of clinical microbiology · 2025Article
- Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice.NPJ vaccines · 2025Article
- Antibacterial Activity of a Natural Clay Mineral againstMicroorganisms · 2023Article
- A Polyclonal Antibody Raised against theBiomedicines · 2021Article
- Evaluation of Antimicrobial Susceptibility Testing Methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from Cystic Fibrosis Patients.Journal of clinical microbiology · 2021Article
- Production and Purification of Two Bioactive Antimicrobial Peptides Using a Two-Step Approach Involving an Elastin-Like Fusion Tag.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Immunization and Immunotherapy Approaches againstVaccines · 2021Review
- Characterization of theVaccines · 2020Article
- Genome-based classification of Burkholderia cepacia complex provides new insight into its taxonomic status.Biology direct · 2020Article
- Investigations into the Structure/Antibacterial Activity Relationships of Cyclam and Cyclen Derivatives.Antibiotics (Basel, Switzerland) · 2019Article
- Variation of Burkholderia cenocepacia cell wall morphology and mechanical properties during cystic fibrosis lung infection, assessed by atomic force microscopy.Scientific reports · 2019Article
- Evaluation of different molecular and phenotypic methods for identification of environmental Burkholderia cepacia complex.World journal of microbiology & biotechnology · 2019Article
- Small Noncoding Regulatory RNAs fromInternational journal of molecular sciences · 2018Review
- Silver Camphor Imine Complexes: Novel Antibacterial Compounds from Old Medicines.Antibiotics (Basel, Switzerland) · 2018Review
- Novel Guanidine Compound against Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species.Molecules (Basel, Switzerland) · 2018Article
- Article
- Burkholderia cepacia complex in cystic fibrosis in a Brazilian reference center.Medical microbiology and immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of cystic fibrosis (CF) patients chronically infected with Burkholderia cepacia complex (Bcc) bacteria requires extensive and aggressive antibiotics therapy, exposing these bacteria to prolonged antibiotics-selective pressure. In the present study, we have compared the susceptibility patterns to 13 antimicrobials of 94 Bcc isolates obtained from 15 Portuguese CF patients in the course of chronic infection during a five-year survey. These isolates were previously genotyped and represent 11 different strains of the species B. cenocepacia (subgroups A and B), B. cepacia, B. multivorans, and B. stabilis. The results are consistent with the notion that CF Bcc isolates are resistant to the most clinically relevant antimicrobials and suggest an uneven distribution of resistance rates among the different species, with B. cenocepacia subgroup A isolates being the most resistant. Phenotypic variants exhibiting differences in the antimicrobial susceptibility patterns were obtained from the sputum samples of clinically deteriorated CF patients during chronic lung infection. The isolation of resistant variants coincided with periods of pulmonary exacerbation and antibiotics therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.